Evaxion to Present Promising Phase 2 Results of Cancer Vaccine at ESMO 2025

Evaxion Biotech ( (EVAX) ) has issued an update.

On July 25, 2025, Evaxion A/S announced that it will present two-year clinical efficacy data from its phase 2 trial of the AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 in October. The vaccine, designed for advanced melanoma, showed a 69% overall response rate and a positive correlation between the AI platform predictions and immune responses. This presentation at a prestigious oncology conference is expected to enhance Evaxion’s visibility and potentially attract new partnerships.

The most recent analyst rating on (EVAX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.

Spark’s Take on EVAX Stock

According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.

Evaxion Biotech’s overall score is driven by its significant revenue growth and positive earnings call outlook, with notable R&D achievements and partnerships. However, financial instability and negative profitability significantly weigh down the score. Technical indicators show some short-term momentum, yet valuation remains a concern due to the lack of profitability and dividends.

To see Spark’s full report on EVAX stock, click here.

More about Evaxion Biotech

Evaxion A/S is a clinical-stage TechBio company based in Denmark, specializing in developing AI-Immunology™ powered vaccines. The company focuses on creating novel immunotherapies for cancer, bacterial diseases, and viral infections using its proprietary AI platform. Evaxion has developed a clinical-stage oncology pipeline of personalized vaccines and a preclinical infectious disease pipeline addressing high unmet medical needs.

Average Trading Volume: 100,830

Technical Sentiment Signal: Sell

Current Market Cap: $3.8M

See more insights into EVAX stock on TipRanks’ Stock Analysis page.